Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hummingbird: DMS in Schizophrenia and Related Disorders
NCT03568500Phase 4Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aripiprazole, olanzapine, quetiapine, risperidone in schizophrenia, schizoaffective disorder, psychosis, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started May 2018; status: completed.
02
Drugs
aripiprazoleolanzapinequetiapinerisperidone
03
Conditions
schizophreniaschizoaffective disorderpsychosis
Beyond the preview
Go deeper on NCT03568500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568500.